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You cannot be wise without some basis of knowledge; but you may easily acquire knowledge 
and remain bare of wisdom. 
 
     Alfred North Whitehead 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my dear parents, 
 (for inspiring me to be who I am) 
 
 
 
 
 
 
 
 4 
List of Contents 
Abstract      5 
List of papers     7 
Abbreviations     8 
 
Definition      9 
Classification     9 
Epidemiology     11 
Mechanisms of AF initiation and maintenance   12 
Atrial remodelling     13 
 
AF management     15 
Pharmacological treatment    16 
 Rhythm control    16 
 Rate control     17 
Non-pharmacological treatment    17 
Stroke prevention     19 
Upstream therapy     19 
 
Consequences     20 
Risk evaluations score     22 
 
Hypotheses      23 
 
Patients and Methods     25 
Patients      25 
Methods      28 
Definitions      33 
Statistical Methods     34 
 
Ethics      35 
 
Results      36 
 
Discussion      56 
Triggers of AF re-initiation early after restoration of sinus rhythm  56 
Role of bradyarrhythmias immediately after successful DC  57 
RV pacing and clinical heart failure after AVJA for drug resistant AF  58 
Prognosis of AF in patients with ischemic heart disease  59 
Role of the CHADS2 score in patients with ACS, with or without AF 61 
 
Conclusions       63 
Clinical implications     64 
Literature      65 
Acknowledgments     75 
 
 
 
 5 
A B S T R A C T 
 
Background: 
Atrial fibrillation (AF) frequently impairs quality of life, but in long-term it is associated with 
an increased morbidity and mortality. Persistent AF may cause changes in the sinus node 
function, and if converted to sinus rhythm (SR), there is a substantial risk of recurrence of AF. 
Atrioventricular junctional ablation (AVJA) is a therapeutic option for patients with drug 
refractory persistent/permanent AF, but permanent right ventricular pacing after ablation, 
according to some reports, has been associated with the development of heart failure (HF). 
Methods: 
172 patients with persistent AF underwent elective DC cardioversion and analysis of 5 
minutes ECG recordings was made in those converted to sinus rhythm (SR).  Another 213 
patients were followed for 6±3 years after AVJA. Forty-nine of the patients (23%) were 
known to have HF before AVJA, and aggravated or new HF was in long-term followed. Of 
2335 consecutive patients admitted with acute coronary syndromes (ACS), 442 had known 
AF (n=204), new AF at admission (n=54) or developed new AF during hospitalization 
(n=184). The short- and long-term mortality and morbidity were followed in patients with and 
without AF, and were related to their CHADS2 scores at admission. 
Results:  
After successful cardioversion of persistent AF, 30% of the patients had a recurrence of AF 
within 1 week. Premature atrial contractions (PAC) were equally frequent in patients with and 
without AF recurrence. A low sinus rate and/or sinus pauses >2 s were observed in 31 patients 
in the first few minutes but did not predict recurrence of AF. One quarter of the patients with 
known HF before AVJA showed an aggravation of HF, while 13% developed new symptoms 
of HF during long-term right ventricular pacing after AVJA. High age and low EF were 
independent predictors of new HF, while high age and coronary artery disease were 
independent predictors of all-cause mortality. In patients with ACS and AF, short-term 
mortality (<30 days) was 13.8%, and differed significantly between the AF subgroups. All-
cause 10-year mortality did not differ between subgroups, as opposed to the rate of 
hospitalization for stroke. The all-cause mortality at 10-years showed a strong association 
with the CHADS2 scores both in patients with and without AF, although strongest in patients 
without AF (hazard ratio [HR] and 95% confidence interval per unit increase in the six-graded 
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CHADS2 score 1.53  [1.42-1.64], p<0.0001 vs 1.28   [1.16-1.43], p<0.0001 after adjustment 
for potential confounders). 
Conclusions:  
PACs and transient sinus bradycardia were the most common potential trigger mechanisms 
after cardioversion of persistent AF, but they did not predict recurrences of AF. AVJA 
followed by right ventricular pacing was associated with aggravated HF in a quarter of 
patients with previously known HF, while development of new symptoms of HF occurred 
much less often. In patients with ACS the type of AF influenced the 30-day mortality and the 
long-term risk of hospitalization for stroke. The CHADS2 score helped to identify patients 
with a higher risk for subsequent stroke and death, both in patients with and without AF. 
 
 
Key words: Acute coronary syndromes, atrial fibrillation, AV junctional ablation, CHADS2 
score, electrical cardioversion, mortality, stroke, trigger mechanisms. 
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ABBREVIATIONS 
 
 
 
ACS – acute coronary syndromes 
AF – atrial fibrillation 
AMI – acute myocardial infarction 
AVJA – atrioventricular junctional ablation 
CHADS2 score - an acronym for Congestive heart failure, Hypertension, Age >75 years,  
       Diabetes and prior Stroke 
CHF – congestive heart failure 
ERAF – early relapse of atrial fibrillation 
IRAF – immediate relapse of atrial fibrillation 
PAC – premature atrial contraction 
SN – sinus node 
SR – sinus rhythm 
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DEFINITION 
Atrial fibrillation (AF) is the most common sustained heart rhythm disorder and has abroad 
variety of presentations in clinical practice. In London in1909, Sir Thomas Lewis established 
AF as a clinical entity and gave it the name “auricular fibrillation” (1, 2). Lewis considered 
AF as a chronic and terminal disease because of heart failure and clots found within the 
auricles.  
Later, AF was described to “occur in a small proportion of mainly elderly patients, usually in 
association with structural heart disease, but many cases are idiopathic (lone atrial 
fibrillation). This rhythm disturbance is entirely benign although it may be fiercely 
symptomatic. It is an acceptable alternative to normal sinus rhythm”(3). In the current 
guidelines of the European Society of Cardiology, the American College of Cardiology and 
the American Heart Association, AF is defined as “a supraventricular tachyarrhythmia 
characterized by uncoordinated atrial activation with consequent deterioration of atrial 
mechanical function (4), and the ventricular response to AF depends on electrophysiological 
properties of the atrioventricular node and other conducting tissues, the level of vagal and 
sympathetic tone, the presence or absence of accessory conduction pathways, and the action 
of drugs” (5). 
 
Fig. 1. Atrial fibrillation 
 
CLASSIFICATION 
AF is a progressive disease and has a variety of clinical presentations. The classification 
terminology has varied with the changes in the definition of AF. The most widely used 
classification tries to include the convertibility and progression of AF (6) and is recommended 
by experts (4).  
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When a patient experiences the first detected episode of AF, it is often difficult to make an 
estimation of its duration, which can be hours, days, months or years. In some cases, the 
termination of the first detected episode of AF, spontaneously or with the help of the 
cardioversion, is not followed by more episodes but does often recur. In the case of self-
termination, AF is called paroxysmal and is characterized by a varied duration of the episode 
and frequency of occurrence. AF is called persistent when AF perpetuates, and cardioversion, 
electrical or pharmacological, is needed to interrupt the sustention of arrhythmia.  Permanent 
AF is ongoing AF when one or more attempts of cardioversion fail and further attempts are 
planned or if attempts are not made because they are regarded not to be meaningful.  
 
 
Fig. 2. Schematic classification of atrial fibrillation (PaAF – paroxysmal, PeAF – persistent) 
 
However, new upcoming techniques of cardioversion, electrical (7), pharmacological (8), 
their combination, catheter techniques (9-11) and AF surgery (12) may result in a restoration 
and maintenance of sinus rhythm (SR) in patients with longstanding AF. Thus the decision to 
leave a patient in ongoing AF is serious and should be made only after careful evaluation of 
the individual patient.  
Despite subjectivity, this classification has been clinically useful in describing the progression 
from paroxysmal to persistent and further to permanent AF, and vice versa. 
 
 
AF 
Permanent  
PaAF     PeAF 
    SR 
  cardioversion 
First detected AF
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EPIDEMIOLOGY 
The prevalence of AF increases steeply with age, affecting 1–1.5% of the population (13). 
The estimated prevalence is  ~ 1 % in the general population (14) and the life-time risk of AF 
for adults of age 40 and older is reported to be 26% in men and 23 % in women (15). 
The prevalence will grow considerably in the next decades owing to several socio-economic 
factors, where most probably increasing life expectancy and improved health care are central 
factors. Projected data from the ATRIA study in California, USA (2001), show that the 
number of Americans with AF will increase 2.5-fold during the next 50 years (14), while in 
Olmsted County, Minnesota, USA (2006), the number of patients with AF is estimated to 
increase 3-fold from 2000 to 2050 (16). The increase of the prevalence in the ATRIA-study 
ranged from 0.1% among adults younger than 55 years to 9.0% in persons aged 80 years or 
older.  
 
Fig.3. Projected number of adults with atrial fibrillation in the United States by 2050.  
(Modified from: Go AS et al.14 and Miyasaka Y et al. 16. ATRIA = AnTicoagulation and Risk Factors In Atrial 
Fibrillation. By courtesy of Professor John Camm) 
 
AF is furthermore associated with an increased risk of stroke and congestive heart failure 
CHF (17-19) and a higher number of hospitalizations compared to other arrhythmias. 
According to surveys done in 2000, the number of hospitalizations because of AF had almost 
tripled compared to the number two decades ago (20). 
In the Framingham Heart study and others AF was associated with an increased risk of 
premature death, and the relative risk of death after adjustment for age and co-morbidity 
varied between 1.2 and 2 (21, 22).   
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MECHANISMS of AF INITIATION and MAINTENANCE   
AF initiation requires a trigger, which can often be a premature atrial contraction (PAC) or an 
atrial tachyarrhythmia (10, 23, 24). A trigger alone can not initiate AF, however, a modulator, 
often the autonomic nervous system, is also necessary (25). Tachyarrhythmia, short- and long 
episodes of AF, create with time an electrical substrate, which helps to re-initiate AF (26-28). 
The saying “AF begets AF” was first used in the middle of 1990s and described, in a goat 
model, that the more AF the goats had, the easier AF could be started after restoration to SR.  
 
 
Fig. 4. Necessary factors for development of atrial fibrillation  
 
Theories on the mechanism of AF can roughly be divided into the single focus theory (mother 
fixed or moving rotor) and the multiple sources theory (multiple foci and wavelets, unstable 
reentry circuits).  
According to the single focus hypothesis, AF occurs due to a single rapid macro-reentry 
circuit, during which its wavefronts originate and then break against regions of varying 
refractoriness by thus creating the irregular activity that characterizes the arrhythmia (29). The 
very rapid rate, which cannot be followed by the entire atrial tissue, produces fibrillatory 
conduction.  
On the other hand, the multiple wavelet hypothesis states that a heterogeneous dispersion of 
repolarization in atria, which creates the special area with a functional conduction block, is 
responsible for wave breaks and the generation of multiple wavelets that sustain AF (30). 
These wavelets incessantly initiate themselves or each other. The area with heterogeneous 
dispersion (lines of the conduction block) surrounds the anatomical structures in the atria, 
which may be different according to acquired anatomical obstacles such as scars, patchy 
Modulator  Substrate 
     Trigger 
AF 
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fibrosis, stretch-induced longitudinal dissociation, or areas of myocardium at different stages 
of recovery and excitability (31, 32).  
Structural changes, such as increased cellular volume and gap junction properties, play a key 
role in the maintenance of the number of simultaneous circuits required for the perpetuation 
of AF. As a result, a critical mass of atrial tissue, serving as an arrhythmogenic substrate 
necessary for re-initiation and sustention of arrhythmia, is already created. Not surprisingly, 
an increase in the left atrial diameter of more than 50 mm has been reported to be proved to 
augment the risk of AF by 40% in population-based studies (33). 
 
 
Fig. 5. Multiple wavelets of atrial fibrillation  
 
During the past decade, the development of modern electrophysiology, especially catheter 
ablation for AF, has further contributed to knowledge about the mechanisms of AF. There is 
evidence that suggests that AF is preserved by rotors or multiple wavelets with a dominant 
high frequency resulting in the distribution of excitation frequencies throughout the atria, and 
from the left atrium towards the right atrium, through spatially distributed conduction block 
patterns (34-36). 
 
 
ATRIAL REMODELLING    
Atrial electrical properties are altered by sustained AF and the atria become more vulnerable 
to the initiation and maintenance of the arrhythmia (26, 28, 31). The alteration in the 
electrophysiological properties and the structure of the atrial myocardium causes a process 
known as atrial remodelling.  Atrial tachycardia-induced electrical remodelling is associated 
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with a shortening of the atrial effective refractory period and the atrial action potential (27, 
37), as well as areas of slow conduction (31). The shortening of the refractory period and 
action potential duration occurs within minutes of the onset of AF and is a consequence of 
altered ion channel function, with calcium overloading in atrial myocytes (38, 39).   
 
 
Fig 6. Atrial remodelling during atrial fibrillation 
 
During continuing AF, structural changes (increased cellular volume, proteolysis and loss of 
contractile elements) may develop that result in a specific type of atrial myopathy and later in 
atrial dilatation (31, 33). As previously mentioned, the alteration will also involve gap-
junctions, with a reduction in connexins Cx40 and Cx43 (40). Fibrosis and/or dilated atria are 
examples of substrates and, together with gap-junctional alteration, such as a contractile 
abnormality, promote the maintenance of AF, once induced (28, 31).  
* Electrical and structural remodelling go hand in hand. Both subsequently create 
the substrate for AF: electrical remodelling starts within hours of an episode of AF and 
facilitates the initiation of new AF episodes, while structural remodelling acts as a second 
factor for perpetuation of AF (26, 41). An understanding of electrical and structural 
remodelling is essential as it explains why paroxysmal AF may become permanent, or why 
AF is difficult to treat. Furthermore, recovery, or reverse electrophysiological and structural 
remodelling, following an episode of AF takes time, leaving a varying period of vulnerability. 
This explains the high relapse rate into AF after an initially successful direct current (DC) 
cardioversion, whether transthoracic or intracardiac (23, 42, 43).   
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Re-initiations of AF have been called immediate (IRAF) when they occur within the first 
minute after cardioversion and early (ERAF) when they occur within the first five minutes 
after cardioversion (23). A number of different AF onset mechanisms have been described in 
the time period immediately preceding an episode of AF, especially episodes captured by 
different devices (23, 44, 45). According to these studies re-initiation occurs after up to 25% 
of recorded short AF episodes, creating a picture of electrical instability. Less is known 
however about the occurrence of such mechanisms and their predictive value when they 
appear during the first minutes after successful external DC cardioversion of persistent AF, 
i.e. episodes of longer duration than in the device studies. Once AF has become persistent, the 
likeliness that relapses will also be persistent, is high. 
* Persistent AF is often associated with a depressed sinus node function, which 
facilitates the perpetuation of AF and reduces the stability of SR (46, 47). Sinus bradycardia, 
sinus pauses and/or sino-atrial conduction block may occur as features of the sick sinus 
syndrome (SSS) also occur after spontaneous conversion of AF (48, 49). In patients with AF, 
sinus bradycardia and pauses after cardioversion can imply pre-existing sinus node (SN) 
dysfunction or AF-induced SN remodelling or reflect normal variations. While SN 
dysfunction has previously been regarded as limited to the SN and its closest atrial 
connections, the initiation and maintenance of AF also require the participation of structures 
outside the SN area. The atria in patients with AF without documented SSS and in patients 
with SSS without documented AF seem to have important patho-physiological and structural 
properties in common (47, 50). However, little is known about how common SN dysfunction 
is in patients with persistent AF and whether it is reversible or predictive of the recurrence of 
AF after successful cardioversion.  
 
 
AF MANAGEMENT  
The management of AF focuses on symptom relief, prevention of late complications and on 
prevention of the progression of AF. Symptom reduction can be achieved by restoration and 
maintenance of SR (rhythm control) and/or modification of the ventricular rate during AF 
(rate control). Sudden onset, sustained and symptomatic arrhythmia require termination 
(cardioversion), and prophylactic therapy must be given to prevent or reduce recurrences, 
while ventricular rate control may be an option in permanent or accepted AF. The most 
important late complication of AF is stroke, and the risk can be greatly decreased by 
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antithrombotic treatment, and another complication promoted by ongoing AF is heart failure 
and/or development of cardiomyopathy (51, 52). 
The intention of rhythm control strategy is to restore and/or maintain SR by also paying 
attention to ventricular rate control. The rate control strategy aims to control the ventricular 
rate and does not involve attempts to restore or maintain SR. In addition to the rate or rhythm 
control strategies is antithrombotic therapy, which consists prevention of thromboembolic 
events. The results of the studies carried out at the beginning of the last decade, which 
enrolled a large number of patients with AF and compared rate and rhythm control strategies, 
showed that a primary rate control strategy was not inferior to the rhythm control strategy in 
terms of mortality and morbidity (53-57). These studies also demonstrated that rhythm control 
strategy was more expensive and complex than the rate control strategy. The trials had 
different patient selection criteria, endpoints and therapeutic interventions, thus limiting the 
applicability of the findings to all AF populations. While it is well recognized that both rate 
and rhythm control strategies are important in AF management, each approach should be 
chosen according to an accurate evaluation of the individual patient. Treatment should be 
based on AF history, type and timing of AF, severity of symptoms, concomitant diseases and 
medication.  
 
Pharmacological treatment  
In patients with severely symptomatic AF, rhythm control strategy is obviously a plausible 
alternative, and more efficient methods to maintain SR are needed to reduce the morbidity 
related to arrhythmia. On the other hand, tachycardia-induced cardiomyopathy, with or 
without signs of heart failure can be induced or developed in patients with 
persistent/permanent AF and rapid ventricular rate during AF and this is the main reason for 
the necessity of an adequate ventricular rate control at rest and activity 
 
Rhythm control 
In patients with ongoing AF one ore more cardioversion attempts are reasonable. In many 
patients, the electrical (external, monophasic or biphasic and internal, catheter-related) or 
pharmacological cardioversion, followed by antiarrhythmic (AA) therapy to maintain SR is 
the main treatment option. Recommended AAs for maintenance of SR include flecainide and 
propafenon for patients without significant underlying structural heart disease, while sotalol 
may be used in patients with structural heart disease. Amiodarone is a second-line drug for all 
subsets of patients with AF. Dofetilide is available in the US but requires special education 
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and certification. Dronedarone has recently been approved for rhythm control in the EU and is 
believed to be at most moderately effective, having its most favourable properties in the safety 
profile.   
A rhythm control strategy is suitable primarily when applied in younger patients, highly 
symptomatic patients, and patients with sudden-onset AF and AF with associated CHF. The 
analysis of subgroups in the AFFIRM trial showed better survival in patients in SR and 
patients on anticoagulant therapy (58).  However, available agents for pharmacological 
rhythm control are neither as effective nor as safe as required, and patients eligible for 
treatment are instead frequently treated with drugs that are not recommended, i.e. beta-
blockers, verapamil and/or digoxin, that may be perceived as safer but have not been proven 
effective for that purpose (59). 
Rate control 
In general, rate control strategy and anticoagulation are suitable in older asymptomatic 
patients. Effective control of the ventricular rate during AF frequently requires more than one 
AA, most frequently a betablocker, digoxin and/or verapamil and adjustments in the type of 
drug and dosage may be needed to achieve the desired effect (60). To add to the problem, 
there is no consensus over a definition of adequate rate control. Lenient rate control, defined 
as a heart rate at rest of <110 beats/min, was very recently shown not to be inferior to strict 
rate control, defined as a heart rate at rest of <80 beats/min, in terms of death from 
cardiovascular causes, hospitalization for heart failure and stroke, systemic embolism, 
bleeding and life-threatening arrhythmic events (61). 
 
Non-pharmacological treatment 
Unfortunately, available AA drugs are moderately effective in reducing recurrences of AF or 
preventing persistent AF, especially in the long term, and patients may during the course of 
AF become refractory against AA drugs or develop side effects. The proarrhythmic risk and 
toxicity of AA drugs is another problem in the management of AF and, in substudies, patients 
treated with AA drugs to restore and maintain SR had a higher mortality risk (58).  
The work done in the past decade has given a better understanding of specific AF 
mechanisms, such as the role of ectopic beats or tachycardias originating from ‘sleeves’ of the 
atrial myocardium inside the pulmonary veins in triggering and sustaining episodes of AF (10, 
62), which has led to the development of non-pharmacological treatment alternatives. A 
variety of techniques for catheter ablation, intra-operative ablation and surgical treatment of 
AF is now available.  Catheter ablation is most effective in patients with paroxysmal and 
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persistent forms of AF, with success rates, depending on the definition, varying between 75 
and 85%, compared to the lower rate of 5–35% in patients on AA drug therapy. The Maze III 
open-heart surgery procedure is the gold standard of non-pharmacological treatment, with 
long-term success rates in terms of SR of >90%, even in patients with longstanding ongoing 
AF, (12, 63).  These figures have stimulated the testing of, so called minimally invasive 
surgical procedures, using an epicardial (thoracoscopic and non-thoracoscopic) approach. The 
results of these procedures are good but have not yet reached the success rates of the cut and 
sew surgical Maze III procedure (12, 64-66).  
* More than one mechanism might be responsible for AF at a given time in the 
clinical course, more than one type of therapy might be necessary. In patients in whom both 
rhythm and rate control strategies have failed another treatment must be selected. Catheter 
ablation of the atrioventricular junction ablation (AVJA), followed by permanent ventricular 
pacing, known as the ‘ablate and pace’ strategy, is such a recommended treatment. This is 
often reserved for older individuals, with drug refractory, symptomatic permanent and/or 
persistent AF (67). AVJA is used to control the ventricular rate in these patients, and its aim is 
to destroy the electrical atrio-ventricular connection. Antithrombotic treatment continues, 
while the benefit consists of rate control and a cessation of previous medication for rhythm 
and/or rate control.  
This palliative treatment, which makes the patient dependent on pacemaker, is used for 
symptom relief as it reduces the ventricular rate, and it is often associated with an improved 
quality of life and exercise capacity and a decreased need of hospitalization (68, 69). While 
many patients have been followed for a long time and have been well, reports have implied 
that long-term right ventricular (RV) pacing may be harmful and might lead to the 
development of symptoms of CHF. This would in turn be explained by systolic dysfunction 
with a reduction of the left ventricular ejection fraction (LVEF) and/or induction of left 
ventricular dyssynchrony, defined as an abnormality in electromechanical coupling and 
detectable with echocardiography (70, 71). 
Patients in CHF have an increased risk of developing AF (72) and AF per se is a predictor of 
CHF and of increased mortality in patients with CHF (66). The development of new HF or an 
aggravation of known HF after AVJA may thus have different causes and the possible 
contribution of RV pacing therefore needs to be explored. 
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Stroke prevention (Antithrombotic treatment) 
AF is associated with an increased risk of stroke, and about 15% of all ischemic strokes are 
estimated to be caused by an embolism caused by AF (17-19). 
The risk of stroke is reduced with anticoagulation treatment,  and all placebo-controlled 
warfarin trials in AF, such as AFASAK, SPINAF, BAATAF, SPAF I, II, III  and the 
SPORTIF trials, have shown great risk reduction with warfarin, and a greater reduction than 
with  aspirin (73-80) . Stroke in warfarin groups, with an INR target of 2 to 2.5 at best, 
occurred after warfarin withdrawal, while a low dose of warfarin with or without aspirin did 
not show a benefit. However, even in eligible patients, undertreatment with warfarin is 
common (81).  A major problem with warfarin is the risk of bleeding and it is a common 
perception among physicians and patients that this risk and the logistics involved in warfarin 
treatment will in many cases make this drug unsuitable or will decrease patient compliance. 
This has increased expectations for new antithrombotic agents, such as the recently approved 
dabigatran, which does not require regular INR testing. This and other new agents appear to 
be promising, but no data concerning long-term efficacy and safety in patients with AF, are 
yet available (82).  
Rate and rhythm strategy trials such as RACE and AFFIRM have stressed that antithrombotic 
treatment should be continued, even when long term sinus rhythm is obtained, and  have 
shown that factors other than rhythm should be taken into consideration in decisions about 
continued antithrombotic treatment.  In the RACE study, 21 of 35 thromboembolic 
complications occurred under rhythm control, mostly in patients receiving inadequate 
anticoagulation therapy (54). In the AFFIRM study, involving patients with one or more 
stroke risk factors, the stroke incidence was also higher in the rhythm control group when 
anticoagulation had been stopped (53). Thus, one major lesson from those randomized studies 
was that anticoagulation should be continued in the presence of risk factors for stroke, even if 
patients are in SR.  
 
Upstream therapy 
Treatment of patients with AF is often started only when patients have had repeated episodes 
of AF or when they arrive with an ongoing episode of AF. At this point in time, atrial 
remodelling might have advanced to make AF more difficult to treat. Upstream therapy is a 
term that has been used to describe that treatment should not only be directed at the triggers 
and/or the substrate but also at the factors that create the substrate.  Pharmacological agents 
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that act in this way are the angiotensin cardioverting enzyme (ACE) inhibitors, the 
angiotensin-renin blockers, the statins and the n-3 polyunsaturated fatty acids (PUFAs).  
Angiotensin II is an important factor in atrial remodelling. Atrial stretch increases local 
synthesis of angiotensin II and is followed by promotion of myocyte hypertrophy, 
proliferation of fibroblast, accumulation of collagen and apoptosis as consequences (83-85). 
In addition, angiotensin II modifies atrial electrophysiology through indirect effects on ion 
channels and may impair gap junction properties (85, 86).  There is currently strong evidence 
that angiotensin receptor blockers and angiotensin converting enzyme inhibitors prevent 
electrical remodelling and reduce interstitial fibrosis in heart failure or rapid atrial pacing 
models of AF, independently of the reduction in intra-atrial pressure (87, 88). These agents 
may reduce the risk of AF by approximately 20%–30% depending on the patient population 
(89, 90). Their efficacy remains to be verified in prospective trials that are under the way.  
Furthermore, agents targeting inflammation, atrial myocyte metabolism and fibrosis could 
theoretically be potential future therapeutic options. The anti-inflammatory and antioxidant 
effects of statins prevent shortening of the atrial effective refractory period (91). In the 
ARMYDA-3 trial, atorvastatin reduced the incidence of in-hospital AF following an open 
heart surgery from 57% in the placebo group to 35% in the treatment group (92).  
These and other observations make probable that these agents prevent or delay atrial 
remodelling during AF. The role of n-3 polyunsaturated fatty acids in preventing or delaying 
AF episodes is less well known, although some reports imply that they may be of value (93, 
94). 
 
 
CONSEQUENCES (short- and long-term) of AF 
Once atrial fibrillation has started, a series of changes are initiated in the heart. The rapid and 
irregular rates of atria and ventricles initiate inappropriate chronotropic responses which, 
together with a loss of atrial systolic function, result in decreased cardiac output, increased 
end-diastolic pressures, decreased blood pressure and tachycardia-mediated atrial and 
ventricular cardimyopathy with CHF, thromboembolism and mortality as consequences (17-
19). 
The association between AF and risk of stroke has long been known. Structural remodelling in 
atria during AF, development of fibrosis (endocardial changes and oedematous or infiltration 
of the extracellular matrix) in different parts of the atria with dilatation as a consequence and 
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loss of atria contraction promote stasis in the left atrium, which is seen as a spontaneous 
echocontrast. Abnormal changes in blood components during AF include haemostatic and 
platelet activation, as well as inflammation and growth factor changes (95, 96). These changes 
result in the Virchow triad for thrombogenesis, which includes abnormal changes in vessel 
walls, blood flow and blood components, resulting in a prothrombotic or hypercoagulable 
state in AF (97).  
The increased burden of AF also contributes to cardiovascular morbidity by causing CHF (4) 
(98) (51). Patients in CHF have an increased risk of developing AF. About 15–30% of them 
are in AF (72), and AF is an independent predictor of increased mortality in the CHF 
population.  
Hypertension and ischaemic heart disease (IHD) play an important role in the development of 
AF, and the presence of AF is associated with increased mortality partly because of stroke. In 
patients with structural heart disease and AF, the relative risk for mortality after adjustment 
for age and comorbidity varies between 1.2 and 2 % (21).  
 
* IHD promotes the development of AF, and AF is not uncommon in patients with 
an acute myocardial infarction (AMI). AF occurs in 5-23% of patients with AMI (99-101) and 
is an independent predictor of increased in-hospital and long-term mortality (101-103). A 
sudden development of AF with an increase in ventricular rate, irregularity of ventricular 
contractions and loss of atrial contribution to left ventricular filling in a patient with acute 
myocardial infarction may result in a deterioration of cardiac function and an increased risk of 
complications such as CHF, ventricular arrhythmias, cardiogenic shock and re-infarction, both 
in the short- and long-term perspectives.  The effects of acute AF on coronary circulation and 
the role of acute coronary syndromes (ACS) in the pathogenesis of AF (104, 105) are well 
known. New onset AF has been associated with poorer in-hospital adverse outcomes and 
previous AF with higher long-term mortality than in patients without a history of AF (106, 
107). Goldberg et al. reported that patients with AMI and AF had in-hospital mortality rates of 
27.6% vs.16.6% in those with SR, and showed the same rates during each of the five years 
studied (108).  Furthermore, the TRACE study, which included 6676 consecutive patients 
with AMI (109), showed that AF was associated with an increased five-year mortality among 
in-hospital survivors, regardless of LVEF and symptoms of CHF.  
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RISK EVALUATION SCORES 
The risk of stroke depends on different clinical presentations such as type of AF, the patient’s 
age, concomitant disease and prior stroke or transitory ischemic attacks. Clinical risk 
stratification is a natural derivation of risk factors identified in large randomized trials.  
The CHADS2 score (an acronym for Congestive heart failure, Hypertension, Age >75 years, 
Diabetes and prior Stroke) is currently used to estimate the risk of ischemic stroke in patients 
with AF (110). In estimating the score, the first four variables give one point and previous 
stroke 2 points and, according to this score, patients with any type of AF and a score of higher 
than one should receive anticoagulation. The CHADS2 score is a simple system that helps to 
make an estimation of the stroke risk in AF patients, but it has been found to be “weak” in 
differentiating patients with “intermediate” risk (111). Restricting the use of the CHADS2 
score to patients with documented AF may underestimate its potential as a prognostic tool 
since episodes of AF may be asymptomatic and can frequently occur without being 
recognized. 
In 2006, another score was proposed in order to pay attention to patients with intermediate 
risk. The Birmingham/National Institute for Health and Clinical Excellence (NICE) schema 
reclassified and included additional risk factors with special attention to the markers of 
thrombogenesis (112). Recently, a novel, simple stroke risk stratification (Birmingham 2009) 
schema was proposed to provide some additional variables in the CHADS2 score, which was 
retrospectively applied in the AF Euro Heart Survey with the intention to evaluate subjects in 
the intermediate risk category (111). This score, CHA2DS2-VASc (CHADS + vascular 
disease, sex category), could according to the authors improve the approach used for 
evaluating stroke risk in patients with AF. From the same survey, de Vos et al. propose the 
HATCH score (an acronym for Hypertension, Age ≥ 75 years, Transient ischemic attack o 
stroke, Chronic obstructive pulmonary disease, and heat Failure) as a tool for estimation of 
AF progression (113). 
Individual clinical components used in different schemas or scores are also risk factors 
commonly seen in patients with other structural heart disease, e.g. ischemic heart disease. The 
CHADS2 score was recently reported to have an impact on all-cause mortality after stroke, 
regardless of whether patients had previously known AF(114). The CHADS2 score was also 
found to be a powerful predictor of stroke and death in patients who underwent angiography 
on suspicion of coronary artery disease, and the existence of AF among these patients 
independently increased the risk of both stroke and death (108). Thus, using the CHADS2 
score in patients with documented AF only may underestimate its role as a prognostic tool.  
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HYPOTHESES 
 
1. Immediate and early relapses of AF are not common during the first five minutes after 
successful external electrical cardioversion of persistent AF.

2.  Premature atrial contractions in the period after successful external electrical 
cardioversion of persistent AF commonly precede recurrences of AF during the first 
week. 

3. Sinus bradycardia and pauses seen in the period immediately after successful electrical 
cardioversion of persistent AF may have a prognostic impact on AF recurrences. 
 
4. Permanent right ventricular pacing is not a common cause of subsequent new heart 
failure in patients after AV junctional ablation. 
 
5. The short and long term prognosis of patients admitted with an ACS differs according 
to whether AF was previously known, whether it was first detected at admission or 
whether it occurred for the first time during hospitalization for ACS.  
 
6. The CHADS2 score can be used as a risk assessment tool for subsequent events, 
including thromboembolism and mortality, in patients with ACS, with or without AF. 
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PATIENTS and METHODS 
Patient evaluation consisted of medical history, risk factors and medication, and other data 
were retrieved from the hospital medical records. 
 
PATIENTS  
I and II 
Between January 2000 and July 2001 172 consecutive patients with persistent AF scheduled 
for elective electrical cardioversion on an outpatient basis were enrolled. Patients were 
referred for DC conversion mainly due to symptomatic AF, but some patients with newly 
diagnosed AF detected as part of routine physical examination for other reasons were 
accepted (Figure 7). There were no protocol-defined exclusion criteria. Patient evaluation 
consisted of a medical history, including number of previous DC cardioversions and duration 
of the current AF episode; physical examination; 12-lead electrocardiogram (ECG); and chest 
x-ray. Laboratory tests included electrolytes, thyroid, and liver tests. Echocardiography was 
performed according to the clinical routine and was available within 6 month prior to DC 
cardioversion in 64 (37%) patients. Eighty-one patients (47%) had undergone at least one 
previous DC attempt.  
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Fig. 7. Patient flow in Paper I 
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Fig. 8. Patient flow in Paper II  
 
III. 
All 213 patients who underwent AVJA for drug refractory paroxysmal (n=103) or persistent/ 
permanent (n = 110) AF at the Sahlgrenska University Hospital during a period of 11 years, 
from January 1994 to December 2004, were included in this retrospective analysis. 
Hypertension, coronary artery disease, and dilated cardiomyopathy were the most common 
underlying conditions. Transthoracic echocardiography was available in 206 patients before 
AVJA. 
 
IV and V. 
 2335 patients admitted to the coronary care unit at Sahlgrenska University Hospital with an 
ACS between 15 September 1995 and 15 March 2001, were enrolled in a study of prognosis 
and its prediction (PRACSIS = Prognosis and Risk of Acute Coronary Syndromes in Sweden) 
(Figure 9) (115).  
The diagnosis of ACS was based on chest pain or other symptoms suggestive of myocardial 
ischemia and had to be supported by electrocardiogram (ECG) changes [ST segment elevation 
≥ 0.1 mV (0.2 mV in V1–V4) or ST depression ≥ 0.1 mV or T wave inversion in at least two 
adjacent leads], biochemical markers above the upper reference level [creatine-kinase (CK)-
MB 5 µg/l and/or troponin T 0.05 µg/l] or previously recognized coronary artery disease. 
Exclusion criteria were: age ≥ 80 years, residence outside the hospital catchment area, life 
expectancy < 1 year because of conditions other than coronary heart disease, previous 
172 consecutive patients 
Unsuccessful cardioversion, n=15 
Relapse <5 minutes, n=8 
Relapse > 5 min & < 2h, n=3 
Technically unsatisfactory 
recordings, n=6 
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inclusion in the study and unwillingness to participate. During the recruitment period, 
approximately 5 % of ACS patients who were admitted to the coronary care unit and lacked 
any exclusion criteria were missed for logistic reasons. The presumed diagnosis of ACS 
turned out to be incorrect in 146 of the 2481 patients enrolled in the study, and these patients 
were excluded from further analysis. 
 
 
Fig. 9. Patient flow in Paper IV and V (Pa – paroxysmal, Pe – permanent) 
 
 
 
METHODS 
I and II 
The patients were allowed to be on antiarrhythmic agents and all were treated with warfarin 
for at least 4 weeks before attempting DC cardioversion. The dose was adjusted to maintain 
an international normalized ratio (INR) target interval of 2.3–3.5. The day before the DC 
cardioversion all patients had a 12-lead ECG recording for rhythm control and a check of the 
serum potassium value. International normalized ratio was checked on the day of the 
procedure. International normalized ratio values varied from 2.0–4.4, and serum potassium 
Previously  
known AF 
(204) 
New AF 
(238) 
 
54 
PeAF 
150 
PaAF 
2335 patients with ACS 
 
1893 pts in SR 
 
442 pts in AF 
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levels varied from 3.7–5.2 mmol/L. The patients were fasting and DC cardioversion was 
performed under brief general anesthesia with propofol. The defibrillator paddles were 
generally positioned over the apex of the heart and below the right clavicle. A maximum dose 
of 5 mg metoprolol intravenously (IV) was given prior to cardioversion in 22 patients with a 
high ventricular rate. A 200–300 J monophasic shock was delivered in a synchronized mode. 
If necessary, another shock of 300–360 J was delivered. A maximum of 4 shocks were given. 
The ECG was monitored with 3–6 leads during the procedure and for 5 min after SR was 
restored. The heart rhythm was monitored for a minimum of 2 h after DC cardioversion, and a 
12-lead ECG was then repeated before discharge at least 2 h after the procedure. Therapy with 
antiarrhythmic agents was continued. All patients returned to the AF clinic for a rhythm 
control with a 12-lead ECG 1 week and 3 months after the procedure. Warfarin therapy was 
continued for at least 3 months after successful cardioversion, and indefinitely in patients in 
whom cardioversion failed or AF relapsed during the 3 months after DC cardioversion. The 
long-term INR values were adjusted individually and controlled by the anticoagulation clinic 
at the hospital.  
A detailed analysis of the ECG recording obtained after DC conversion was made after the 
procedure. In paper I, the heart rhythm was analyzed in relation to IRAF and ERAF during 
the first 2 minute because all ERAF occurred during the second minute only. However, the 
entire 5-minute period was analyzed to identify predictors for AF recurrence during the first 
week after discharge (n = 45). In addition, for the purpose of the latter analysis, a control 
group of 45 patients with SR was formed, and they were matched for age and gender with the 
AF recurrence group. In paper II, patients who were not possible to cardiovert, relapsed into 
AF within 5 minutes and before discharge or had technically unsatisfactory ECGs during and 
after cardioversion were excluded from analysis. Care was taken to assure good quality 
recordings for identifying P waves. All assessments were made on a beat by beat basis: PP 
and RR intervals were measured; P waves were adjudicated as sinus or of other origin. All 
premature atrial contractions (PAC) were counted. 
 
III. 
Ablation, Pacemaker Implant Procedure, and Follow-Up 
At the beginning of the period, a permanent pacemaker was implanted on the day of AVJA. 
After a change in the routines later on in the period, this was done at least 1 month before 
AVJA. The right ventricular lead was placed in the apex region in all patients, and 128 
patients also received an atrial lead in the right atrial appendix. The AVJA was performed 
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with the patient in the fasting state and under conscious sedation. The permanent pacemaker, 
if already in place, was programmed to the lowest VVI rate. A bi- or quadripolar electrode 
catheter was placed in the right ventricular apex region via the right femoral vein for pacing 
when necessary during the procedure. An ablation catheter was introduced to the His bundle 
region via the right femoral vein. All patients were treated with radiofrequency ablation, at 
first using power control and, when it became possible, temperature control. The ablation 
endpoint was the creation of a complete AV block persisting for at least 30 minutes.  
 
  
 
AV junctional ablation and ECG during the ablation  
 
At the end of the procedure, the permanent pacemaker was programmed to VVI(R) mode, or 
alternatively to DDD(R) mode, at a basic rate of 70–80 beats per minutes, which had to be 
maintained for at least 3 weeks before programming to a lower rate was allowed. A second 
Ablation catheter 
Catheter induced AV-block  
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ablation procedure was necessary in 14 patients due to primary failure or recurrent AV 
conduction. After successful AVJA, antiarrhythmic agents were most frequently discontinued. 
β-blockers were still prescribed in 70 and digitalis in 35 patients for other reasons than rate 
control. Warfarin therapy was continued in 161 patients and aspirin was prescribed in 42 
patients.  
Clinical baseline data for all patients were retrieved from our ablation registry. The hospital 
records provided a detailed medical history, results of physical examinations, laboratory tests, 
and 12-lead electrocardiogram (ECG). Transthoracic echocardiography was routinely 
performed as a preablation procedure.  
The first follow-up visit took place at the outpatient pacemaker clinic 1 month after the 
procedure. This assessment included a 12-lead ECG, an interrogation of the pacemaker 
including pacing parameters, settings, arrhythmia history, and histograms, when available, 
and a determination of the pacing thresholds. Pacing rate, mode, and other settings were 
programmed as needed.  
The following visits took place at regular 6- or 12-month intervals and at new symptoms. All-
cause death was also recorded. The time of each diagnosis and/or death was recorded to allow 
for the construction of a Kaplan-Meier curve to show freedom of events.  
Outcome Measures  
The primary outcome measure was the combination of new and aggravated HF during follow-
up. Details on new and aggravated HF were also reported separately. All-cause death was 
recorded as a secondary outcome measure. In addition, a composite endpoint was formed by 
combining all three kinds of events, that is, new and aggravated HF and all-cause death.  
IV and V. 
Clinical data, including information relating to previous clinical history, risk factors and 
medication, were collected from hospital medical records. At admission, all patients were 
interviewed by an experienced study nurse, who specifically explored previous episodes of 
atrial fibrillation. ACS specific information such as delay times between the onset of 
symptoms and hospital admission, clinical presentation and ECG on arrival, as well as ECG 
changes during the hospital stay, was registered. Twelve-lead ECGs at a recording speed of 
50 mm/s were used. Complications, including arrhythmias, medical treatment and 
investigations, were recorded in detail during in-hospital care. At discharge, medical 
treatment, planned investigations, revascularization procedures and the time spent in the 
hospital were documented.  
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Patients with AF could have a history of AF, and/or AF on admission, or could have their first 
AF in the hospital. The CHADS2 score (an acronym for Congestive heart failure, 
Hypertension, Age >75 years, Diabetes and prior Stroke), used to estimate the risk of 
ischemic stroke in patients with AF (110), was calculated from data collected at admission. 
Patients with scores of 3, 4, 5 and 6 were few, and the scores were therefore divided into four 
subgroups with scores of 0, 1, 2 and > 2.  The CHADS2 score could not be determined in five 
patients with AF and three without AF because of missing data. Survival confirmation and 
dates of death as of January 1, 2007 were obtained from the Swedish National Population 
Registry and the incidence of stroke (International Statistical Classification of Disease, Ninth 
Revision (ICD-9) codes 431, 432, 433 or 436 or Tenth Revision (ICD-10) codes I61, I62, I63 
or I64), AMI (ICD-9 code 410 or ICD-10 code I21 or I22) or hospital admission for atrial 
fibrillation (ICD-9 code 427D or ICD-10 code I48) were obtained via linking to the National 
Swedish Diagnosis Registry for hospitalized patients. Ten patients were lost during follow-up 
due to emigration. 
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Definitions: 
* Immediate and early re-initiations of AF were defined as re-initiation within the first 
minute, IRAF, and within the first 5 minutes postcardioversion, ERAF (23).  
 
* Premature atrial contraction density was defined as the number of PACs/minute, and the 
PAC burden was defined as the total number of PACs during the 5-minutes recording. 
 
* Prematurity index is the ratio between the coupling interval of PAC and the preceding RR 
interval, where the coupling interval is the one between a PAC and the previous sinus beat.  
 
* Variations in the rhythm and rate before AF relapse were also analyzed, including sudden 
drop in heart rate (>15 bpm during the preceding 4 beats) and brady-tachy phenomenon (>30 
bpm variation compared with a reference of 60–90 bpm 1 min prior to AF relapse) (45). 
 
* Sinus bradyarrhythmia was diagnosed in the presence of a sinus rate <40 bpm calculated 
from ≥ 2 consecutive P-P intervals and /or a sinus pause >2 s (116).  
 
* CHF was diagnosed if at least two of the following criteria were present: New York Heart 
Association functional class >2, an LVEF lower than 45%, and when pharmacological 
treatment for CHF was prescribed. Aggravated CHF was defined as an increase in the 
functional class by at least one degree when indicated or on the basis of the symptomatology 
at examination, anamnestic details, and/or prescription of one or more additional drugs for 
CHF.  
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STATISTICAL METHODS 
Data are presented as percentages or as means ± standard deviation (SD). All P-values are 
two-tailed and considered significant if below 0.05. 
I. 
Student’s t-test has been used for paired comparisons of continuous variables. Multiple 
logistic regression analysis was used for assessing the predictive value of tentative prognostic 
factors after successful external electrical cardioversion of persistent AF. 
II. 
Unpaired t-test was used for comparison of continuous variables. Fisher’s exact two-tailed test 
was used for comparison of categorical data. 
III. 
We applied a two-step strategy to identify independent predictors of the composite endpoint 
of new or aggravated CHF during follow-up. We first univariately tested the variables of age, 
gender, type of AF, bundle branch block, EF, left atrial area, left ventricular end diastolic 
diameter, and history of coronary artery disease, hypertension, diabetes, and HF. From this 
analysis all variables with a P <0.20 (age, bundle branch block, EF, left atrial area and history 
of coronary artery disease, and CHF) were tested for inclusion in a multivariable Cox 
proportional hazards model, using a forward stepwise selection mode and P < 0.05 as a 
condition for remaining in  the model. This two-step strategy was also used for mortality 
(where age, EF, and a history of coronary artery disease, hypertension, and diabetes were the 
variables with a univariate P < 0.20).  
IV. 
Fisher’s exact test was used for dichotomous variables, when testing for any difference among 
the four AF subgroups and Kruskal-Wallis test for continuous variables. The log rank test was 
used in analysis of mortality and morbidity during follow-up, and Kaplan-Meier estimates 
were used for construction of cumulative mortality and hospitalization rates. 
Cox proportional hazard model in a forward stepwise mode was used to identify predictors of 
all-cause long term mortality in the AF group. The following variables were tested for 
inclusion in the model: age, sex, previous infarction, angina, heart failure, diabetes, 
hypertension, stroke, hypercholesterolemia, bypass surgery, percutaneous coronary 
intervention, valve surgery, smoking habits, index diagnosis and peak creatine-kinase (CK)-
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MB. A p-value below 0.05 was needed for inclusion as well as for staying in the model at 
each step in the selection procedure.  
All tests are two-sided and a p-value below 0.05 was considered statistically significant for 
overall comparisons of the four AF groups. In addition, a p-value below 0.01 was needed for a 
difference to be considered significantly different in the pair-wise two-group comparisons 
regarding CHADS2 score, mortality and morbidity. 
V. 
The 6-graded CHADS2 score was used in all p-value calculations of association with 
outcome, except where explicitly stated. Comparisons were made between patient groups 
regarding the CHADS2 score with the Mann-Whitney U test. The log rank test and Cox 
proportional hazards model were used to test associations between the CHADS2 score and 
mortality and hospitalizations for stroke. The latter was also used to calculate hazard ratios 
and corresponding confidence intervals. Kaplan-Meier estimates were made to assess 
cumulative mortality and morbidity with all data available up to January 2007. For morbidity, 
an individual who died during follow-up before an event had occurred was censored at the 
time of death.  
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RESULTS  
 
I. Burden and timing of premature atrial contractions after electrical 
cardioversion of persistent atrial fibrillation do not predict its recurrence 
 
Recurrence of AF during the first five minutes after DC 
Initially, SR was obtained in 157 (91%) of the 172 patients (Figure 7). Eight patients had a 
relapse of AF within five minutes, and three of these were IRAFs. All five ERAFs occurred 
during the second minute after conversion. Several observations were made in these patients 
(>1/patient): AF was preceded by one PAC in two patients, by one premature ventricular 
contraction in three patients, and spontaneously started in three patients. Premature atrial 
contractions of two morphologies were seen in one patient before relapse, and PACs in 
bigemini were noted in another patient; both having IRAF. An increasing number of PACs 
was observed before relapse in three patients. The heart rate during the last ten RR intervals 
before relapse was 60–90 bpm in three patients and <60 bpm in four patients. A sudden drop 
in heart rate was noted in two patients and a brady-tachy phenomenon in another patient. Each 
patient with IRAF or ERAF thus displayed two or three possible onset mechanisms. All 
patients with IRAF/ERAF received additional DC shocks. Re-cardioversion restored SR in 
five patients, while it was unsuccessful in three patients. Another three patients relapsed into 
AF after the first five minutes, but before discharge, and 151 patients had SR at the time of 
discharge. 
AF recurrence during the first week 
Sinus rhythm was recorded in 106 (70%) of 151 patients (78 men) at the one-week rhythm 
control, among them only two of the originally eight patients with IRAF/ERAF. The mean 
age was 68±11 years and the duration of AF before DC cardioversion was 5.8±4.1 month. 
The characteristics of the two matched groups of 45 patients each with and without AF 
relapse within the first week are presented in Table 1. The focus of this part of the analysis 
was the role of PACs as potential predictors of re-initiation of AF within the first week after 
cardioversion. Comparisons were made regarding the PAC density, the mean coupling 
interval of PACs, the prematurity index for the first two minutes after DC cardioversion, and 
the PAC density during the first five minutes after cardioversion. No differences were found 
between the groups except that patients with recurrences had an AF episode duration of 
5.9±3.4 months compared with 3.8±1.6 months in patients who maintained SR (p<0.003).  
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Table 1: Age and gender-matched comparison between patients with and without AF recurrence at the 1-week 
follow-up visit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A multiple logistic regression analysis including age, gender, AF duration>3 months and 
PACs in relation to AF recurrence during the first week did not reveal any independent 
predictor of AF recurrence.  
 
 
II. Transient impairment of sinus node function immediately after electrical 
cardioversion of persistent atrial fibrillation 
Fifteen of the 172 consecutive patients could not be cardioverted; eight relapsed within five 
minutes, three relapsed before discharge (> 5 min) and six had technically unsatisfactory ECG 
recordings. The study population therefore comprised 140 patients (Figure 8). Sinus 
bradyarrhythmia (SB) was present during the first minute after conversion in 31 patients (21 
men; 22%, 95% CI: 15-29%) and the index cardioversion was their first in 14 of them (45%). 
Twenty-seven (87%) patients had a sinus bradycardia <40 bpm and 16 (52%) sinus pauses ≥2 
s (ten of them >3s; 32%); 12 (39%) had both.  
     AF     SR      p-value 
 
Sex (men/women)   30/15    30/15 
 
Age (y)    70±9   70±10 
 
AF duration of index episode (mo)  5.9±3.4   3.8±1.6      0.003 
 
PAC density, 1st min, n   3.0±3.7   3.6±3.5        ns 
 
Range   (1–20)   (1–14) 
 
PAC density, 2nd min, n   3.5±4.5   3.9±3.8         ns 
 
Range    (1–21)  (1–15) 
 
Coupling interval, msec   571±244   610±265               ns 
 
Preceding RR, msec   846±390   915±387               ns 
 
Prematurity index       62%       60%         ns 
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Altogether, 53 patients had undergone at least one previous cardioversion. There was no 
significant difference in age, duration of the index AF episode, proportion of men vs. women, 
or therapy with anti-arrhythmic or beta-blocking substances in patients with vs. without SB. 
Patients with SB had a significantly lower mean heart rate during the first minute after 
cardioversion (57±13 vs. 63±11 bpm; p < 0.05), but the average rates at each of the 
subsequent four minutes and during the entire five-minute period were not significantly 
different.  The number of PACs during each minute varied among patients but the mean 
number was similar across the five minutes and there was no significant difference between 
patients with vs. without SB. 
 AF recurrence at one week and three months (Table 2) 
In total, 58 patients (41%) relapsed into AF within the first week. Fourteen of the relapses 
(45%) occurred in the group of patients with vs. 44 (40%) among those without SB (ns). In 
the former group one patient with AF at the one-week follow-up was cardioverted once more 
and remained in SR at three months, at which time 21 (68%) patients with SB were in AF vs. 
58 (53%) patients without (ns). We found no relation between AF recurrence and factors such 
as age (>75 vs. ≤75 years), gender and AF duration (>3 months vs. ≤3 months). However, SB 
was significantly more common in patients with antiarrhythmic therapy. Baseline 
characteristics were compared in relation to AF recurrence at one week and three months and 
no statistically significant differences were found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 39 
Table 2. Atrial fibrillation (AF) recurrence at 1 week and 3 months follow-up in relation to specified sub-groups. 
Proportions are presented with 95% CI within brackets. 
 SB 
31 (22%; 15-29) 
Normal SR 
109 (78%; 71-85) 
  AF at 1 week      AF at 3 months 
14                       21 
(45; 27-64)           (68; 48-83) 
AF at 1 week    AF at 3 months 
44                       58 
(40; 31-49)         (53; 44-62) 
 Age > 75 years 6 
(43; 18-71) 
9 
(43; 22-66) 
15 
(34; 20-50) 
17 
(29; 18-43) 
 Gender (F) 6 
(43; 18-71) 
8 
(38; 18-62) 
16 
(36; 22-52) 
22 
(38; 26-52) 
AF duration >  
3 months 
11 
(79; 49-95) 
17 
(81; 58-95) 
25 
(57; 41-72) 
37 
(64; 50-76) 
AA drug therapy 14 
(100; 77-100) 
21* 
(100; 84-100) 
39 
(89; 75-96) 
40 
(69; 55-80) 
   AA antiarrhythmic; AF atrial fibrillation; CI confidence interval; F female; SB sinus     
   bradycardia and/or pauses; SR sinus rhythm; *p < 0.01 for comparisons between the sub-  
   groups at 3 months  
 
III. New or aggravated heart failure during long-term right ventricular pacing after    
AV junctional catheter ablation 
Incidence and role of new HF or aggravated HF after AVJA 
213 patients underwent AV junctional ablation. Forty-nine (23%) patients, 28 of them men, 
were known to have been diagnosed with HF before AVJA and were on appropriate 
medication (Table 3). Thirty-eight patients had permanent AF: 11 patients had complete 
bundle branch block, five right bundle branch block and six left bundle branch block. At 
ablation, 32 patients had already had a single-chamber (VVI) pacemaker implanted for other 
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reasons than the AVJA. The EF was 46 ± 14, the left ventricular end diastolic diameter 58 ± 8 
mm and the left atrial area 29 ± 8 cm. 
 
Table 3.  Baseline demographics in patients with documented HF before AVJA and exaggerated or new HF 
during follow-up 
 
 
Heart failure          Documented Exaggerated      &      New heart failure
         before AVJA                during follow-up 
n                  49          13       22  
Age, years              73 ± 12    72 ± 16  76 ± 10 
Men : women, n (%)                28(57) : 21(43)      8 : 5  12 : 10 
Permanent AF/                         38(78) / 11(22)      5 / 8  11 / 10 
Paroxysmal AF, n (%) 
Dilated cardiomyopathy, n (%)        20 (41)         5       4 
RBBB : LBBB, n (%)               5(1.1) : 6(1.2)      3 : 1    2 : 0 
PM, n (%)                            17(35) : 32(65)      5 : 8  13 : 9 
(DDD mode:VVI mode)          
Beta-blockers, n (%)               31 (63)         7       6 
ACE-inhibitors, n (%)                32 (65)         6       5 
Diuretics, n (%)               34 (69)         9       7 
EF (%)                46 ± 14    45 ± 14    51 ± 11   
LVDD, mm                58 ± 8    56 ± 8    52 ± 9   
Left atrial surface area, cm2             29 ± 8    29 ± 9    25 ± 6   
___________________________________________________________________________ 
ACE – angiotensin convertase enzyme, AF – atrial fibrillation, AVJA – atrio-ventricular 
junctional ablation, EF – ejection fraction, LBBB – left bundle branch block, LVDD – left 
ventricular diastolic diameter, PM – pacemaker, RBBB – right bundle branch block. 
 
 
Figure 10 shows the Kaplan-Meier curve for the combination of having new or aggravated 
HF during follow-up. The Cox proportional hazards regression analysis revealed age (per five 
years) as the only significant risk factor, 1.19 (95% confidence interval [CI]: 1.00–1.41), p = 
0.047, while LVEF (per 5%) significantly lowered the risk, 0.76 (95% CI: 0.67–0.87), p < 
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0.0001. Thirteen of 49 patients (26%) developed aggravation of known HF during follow-up. 
This occurred in five patients with permanent AF and eight patients with paroxysmal AF at 
baseline, and all were detected within three years after AVJA. Ten patients (20%) died 38 ± 
31 months after AVJA, six of whom were in permanent AF and four in paroxysmal AF before 
AVJA. Three of these patients died of HF 15, 35 and 110 months after AVJA (mean 53 ± 33 
months). Their baseline EF was 20%, 60% and 30%, respectively. There were no later EF 
values in the latter two patients, while it remained at 20% in the first. Twenty-two patients 
developed new HF during follow-up and were detected at a mean time of 44 ± 37 months 
after AVJA, with 50% occurring at a time less than three years after ablation. Eleven patients 
each were in paroxysmal and persistent/permanent AF before AVJA. Six patients died during 
follow-up, one of HF. 
 
Fig. 10. Freedom from new or aggravated HF 
 
Multiple logistic regression analysis identified age per five years (odds ratio [OR] 95% CI 1.5 
(1.0–2.0), P = 0.02) and EF per 5% (OR 95% CI 0.7 (0.5–0.8), P = 0.008) as independent 
predictors of an increased and a decreased risk of developing HF during follow-up in patients 
with no signs of HF before ablation. For the patients with known HF at baseline, none of the 
variables tested were significantly associated with a worsening of their HF during follow-up. 
All-cause mortality 
The all-cause mortality was 16%, 35 patients (18M : 17F), occurring at a mean time of 47 ± 
30 months after AVJA. Their mean age at AVJA was 78 ± 11 years. Cause of death could be 
established in 27 patients. Four patients died of deteriorated HF, eight of age, one as a result 
of brain hemorrhage, nine of myocardial infarction, two of cancer and three patients of 
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pneumonia. Seventeen patients were in paroxysmal AF at AVJA. Figure 11 shows the 
estimated freedom from all-cause death in our population. Two predictors of all-cause 
mortality were identified in the Cox proportional hazards regression analysis: age (per five 
years), hazard ratio 1.30 (95% CI: 1.08–1.56), p < 0.005, and coronary artery disease, hazard 
ratio 2.58 (95% CI: 1.26–5.31), p < 0.01 
 
Fig. 11. Freedom from all-cause death 
 
IV. Short-term and long-term prognosis in relation to type of atrial fibrillation in 
patients with acute coronary syndromes 
Prevalence and incidence of different types of AF at the time of ACS 
Four hundred forty-two (71±8 years, range 67 to 76 years, 142 women) out of 2335 ACS 
patients had or developed AF. AF was previously known in 204 patients, persistent/permanent 
in 54 and paroxysmal in 150. New AF was seen at admission in 54 patients and AF developed 
during hospitalization in 184 (Figure 9). At admission, 145 patients were in ongoing AF, 54 
with known persistent/permanent AF, 37 with known paroxysmal AF and 54 who with their 
first detected AF. Altogether, 70 patients left the hospital in AF, i.e. all 54 with 
persistent/permanent AF, eight of 54 with new AF at admission and eight of the 184 patients 
with new AF that developed in hospital.  
At admission, the rates of previous AMI, angina, bypass surgery, percutaneous coronary 
intervention, hypercholesterolemia and CHF were significantly different among the sub-
 43 
groups. CHF was most often observed in patients with persistent/permanent AF (39%), while 
AMI, angina and hypercholesterolemia were most frequently seen in patients with known 
paroxysmal AF, 42%, 71% and 35%, respectively. The prevalence of previous stroke differed 
among the sub-groups (p=0.04), with the highest observed proportion in patients with 
persistent/permanent AF (20%) and the lowest in those with new AF at admission (8%). 
There was a significant difference in diagnosis among the sub-groups, with the highest 
observed rate of ST segment elevation myocardial infarction (STEMI) in patients with new 
AF in hospital (54%), of non-STEMI in patients with AF at admission (56%) and of unstable 
angina in patients with known paroxysmal AF (31%). A significant difference among the 
subgroups was also seen in ventricular arrhythmia during hospitalization, where the highest 
observed proportion was in patients with new AF in hospital (45%).  
It is of note that only 14% of patients with any AF were on warfarin at admission, most of 
them patients with known persistent/permanent AF (41%). Of patients with previously known 
paroxysmal AF, 18% had warfarin as prophylactic anticoagulation therapy. 
CHADS2   scores at admission 
There was a significant difference in CHADS2 scores among the subgroups, with the highest 
observed scores in the two sub-groups with previously known AF. In pair-wise sub-group 
comparisons, patients with new AF in hospital significantly differed from patients with both 
types of previously known AF, as did patients with new AF at admission from those with 
previously known persistent/permanent AF (Table 4). 
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Short- and long-term mortality and stroke in AF subgroups 
There was a significant difference in mortality among AF subgroups at 30 days (p=0.02) 
(Table 5). The mortality was significantly higher in patients with previously known 
persistent/permanent AF than in patients with paroxysmal AF. Patients with previously 
known paroxysmal AF had the lowest observed early mortality (7.3%), and this was similar to 
that of patients without AF (5.2%).  
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The ten-year mortality did not differ significantly among the four AF sub-groups. Patients 
with persistent/permanent AF had the highest observed mortality at ten years, 78.1%. The 
Kaplan-Meier curves demonstrating the all-cause ten-year mortality are shown in Figure 12. 
 
 
 
 
 
 
 
 
Fig. 12. All-cause mortality in the four sub-groups of atrial fibrillation 
 
During the index hospitalization, ranging from a mean of six to nine days across the sub-
groups, new stroke occurred in 4% of patients with new AF developed during hospitalization, 
in 2% of those with AF at admission and in 1% of patients with previously known paroxysmal 
AF, while no stroke occurred in patients with previously known persistent/permanent AF. At 
discharge, 19% of patients with any AF were on warfarin, implying that new AF in the acute 
phase of an ACS was not regarded as an indication to start anticoagulation. The 
hospitalization rate for stroke differed significantly among the sub-groups during long-term 
follow-up  (p=0.007), being most frequent in patients with known paroxysmal AF, 40.3%, 
followed by new AF on admission, 31.3%; the lowest observed proportion was in patients 
with new AF during hospitalization, 15.6% (Table 5). In pair-wise comparisons the latter 
proportion was significantly lower than that observed in patients with previously known 
paroxysmal AF.  
Predictors of long term mortality 
Five variables were identified as predictors of long-term mortality in the total study group of 
AF patients. These were age (p<0.0001, with a hazard ratio (HR) of 1.06 per year and a 
 48 
corresponding 95% confidence interval (CI) of 1.04-1.09), previous AMI (p=0.04, HR 
(95%CI): 1.4 (1.0-1.8)), previous CHF (p=0.0002, HR (95%CI): 1.8 (1.3-2.4)), previous 
diabetes (p=0.0005, HR (95%CI): 1.7 (1.2-2.2))  and current smoking at admission (p=0.001, 
HR (95%CI): 1.7 (1.2,2.3)). Table 6 shows these variables separately for the four AF sub-
groups. The impact was similar across these sub-groups for all predictors except previous 
AMI, which differed statistically significantly between patients with previously known 
persistent/permanent AF and those with new AF at admission and new AF in hospital (p for 
interaction = 0.0007 and 0.03, respectively), and between patients with previously known 
paroxysmal AF and those with new AF at admission (p for interaction = 0.02). 
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V. Role of the CHADS2  score in acute coronary syndromes – risk of subsequent 
death or stroke in patients with and without atrial fibrillation. 
CHADS2 score in patients with and without AF  
Almost half of the patients with AF (n=442 patients) had a CHADS2 score equal to or greater 
than 2 as compared with one quarter of the patients without AF (n=1893 patients) (Table 7). 
Patients with AF had a mean score of 1.6±1.4 versus 1.0±1.1 for patients without AF, 
p<0.0001.  
Table 7. CHADS2 score at baseline in acute coronary syndrome patients with and without atrial fibrillation 
     Patients          Patients                       
  without AF (%)   with AF (%)   
                                         (n=1893)      (n=442)     p      
___________________________________________________________________________ 
CHADS2 score         
     0                                             40        22                 
     1                                             33                       30                 
     2                                             16                      26                        
     3                                               6                     12                        
     4                                               3                         6                       
     5                                               1                         3                     
     6                                          <1                       1                   
mean±SD                            1.0±1.1         1.6±1.4  <.0001                       
AF – atrial fibrillation   
 
The burden of previous cardiovascular diseases was somewhat greater in patients with than 
without AF. Patients with any AF were older and more often had previous heart failure. 
Previous stroke was almost equally frequent in both groups. With the exception of previous 
percutaneous coronary interventions (PCI), indicators of ischemic heart disease were more 
frequent with increasing CHADS2 score in both groups. The CHADS2 score correlated 
inversely with STEMI in both groups whereas non-STEMI was more frequent at higher 
CHADS2 scores in patients with AF. 
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Early and long-term mortality 
Survival analysis showed that patients with AF had a higher risk of dying than those without 
AF (Figure 13).  
 
 
 
            
 
            p < 0.0001 
       
 
 
 
 
 
Fig. 13. All-cause mortality in patients with and without AF 
 
Early mortality (less than 30 days) was higher in patients with than without AF but was 
related to the CHADS2 score only in patients without AF (Table 8).  Thus the risk of dying 
within 30 days was doubled to tripled at CHADS2 scores of 0, 1 and 2 and, at CHADS2 score 
>2, the risk remained somewhat elevated in patients with AF as compared to patients without 
AF. 
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All-cause 10-year mortality showed a highly significant association with the CHADS2 score 
in both groups. The mortality rates observed at CHADS2 score 0 were 41.1% and 21.2%, and 
at CHADS2 score 1 were 59.7% and 33.4%, in patients with and without AF, respectively. At 
scores of 2 and higher, the differences remained but were smaller. The absolute mortality 
level exceeded 50% in both groups, and patients with AF had a 10-year all-cause mortality 
rate of 84.8%. The Kaplan-Meier curves demonstrate that the all-cause 10-year mortality in 
patients with AF (Figure 14) and without AF (Figure 15) increased as the CHADS2 score 
increased. However, in each of the CHADS2 score subgroups, including score 0, the mortality 
risk was consistently higher in patients with AF. Thus the risk of dying within 10 years was 
almost doubled at CHADS2 scores 0 and 1, while this difference disappeared at higher scores. 
The all-cause mortality was lower regarding CHADS scores 0, 1 and 2 in patients without AF, 
while the curves showing CHADS score >2 were almost similar in both patients without and 
with AF. 
 
Fig. 14. Cumulative all-cause mortality during follow-up in relation to CHADS2 score on admission in patients 
with AF (n=437) 
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Fig. 15. Cumulative all-cause mortality during follow-up in relation to CHADS2  score on admission in  patients 
without AF (n=1890). 
 
All-cause mortality correlated significantly with CHADS2 scores, both unadjusted and when 
adjusted for potential confounders. The association was stronger in patients without than 
patients with AF.  
Incidence of hospitalization for stroke during long term follow-up 
The risk of hospitalization for stroke in the 10 years of follow-up showed an increasing rate 
with higher CHADS2 score in both patients with and without AF (Table 8). 
In patients with AF and CHADS2 scores 1 and 2, stroke occurred early and increased through 
the first seven years (Figure 16). The risk was much lower for CHADS2 scores >2 and 
increased slowly until a steep increase occurred at the beginning of year 4. The pattern in 
patients without AF was different, with patients with a CHADS2 score >2 demonstrating the 
highest risk and the others showing a very low risk during the first two years, which thereafter 
increased but at a slower rate than in patients with AF (Figure 17).  
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Fig. 16. Cumulative hospitalization for stroke during follow-up in relation to CHADS2  score on admission in 
patients with AF (437).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 17. Cumulative hospitalization for stroke during follow-up in relation to CHADS2 score on admission in 
patients without AF (1890) 
 
The CHADS2 score was significantly associated with the rate of hospitalization for stroke in 
patients without AF, both unadjusted and after adjustment for potential confounders. 
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DISCUSSION 
Triggers of AF re-initiation early after restoration of sinus rhythm 
While premature atrial contractions were common, neither the PAC burden nor PAC 
prematurity predicted recurrence of AF during the first week. A short duration of the AF 
episode was the only predictor of the maintenance of SR, and sinus bradycardia during the 
first minute after successful electrical cardioversion had no prognostic effect on short term AF 
recurrence, pacemaker implant rate or survival during long term follow-up.  
The rate of IRAF/ERAF was 4.6% in our population of persistent AF patients, which is 
consistent with one report (23) but in contrast to others that have dealt with spontaneous or 
internal electrical conversion of AF episodes of very short durations (42, 44). Six of our eight 
patients with IRAF/ERAF relapsed into AF within the first week, which probably implies the 
presence of a substrate making SR more difficult to maintain.  In the case of AF episodes of 
short duration, Gorenek et al. found a recurrence rate within one minute of 27% and observed 
that 73% of the recurrences were initiated by PACs, which were found in only 12% of 
patients who did not experience immediate recurrence of AF (117). These conflicting results 
may be explained at least in part by the heterogeneity of patient populations. Oral et al. found 
that recurrences within one minute were more likely when the duration of the AF episode was 
less than one hour than when it was longer than 24 hours (56% versus 12%; p<0.001) in 
patients undergoing electrophysiological procedures (118). Similar results were observed in a 
small study involving 17 patients with an implantable defibrillator, where AF episodes were 
electrically cardioverted by the patients’ activation after a mean of either 6.8 h or of 34.7 
hours (119). Our study population had a considerably longer AF episode duration than these 
studies. In general, the IRAF and ERAF rate seems to be inversely related to the duration of 
the AF episode.  
While the few IRAF/ERAFs conferred a high likeliness of recurrence of AF, PACs and 
patterns of PACs did not. This is consistent with the results of another study, where neither 
the frequency of PACs nor the number and length of runs of PACs during the first 24 h 
following DC cardioversion predicted the recurrence of AF (120). Device studies have 
identified a number of onset mechanisms in analyses covering several minutes preceding AF 
initiation (23, 44, 45, 121). We chose to test the trigger mechanism definitions described in 
one such study (45), that showed that more than one possible onset mechanism per patient are 
often observed and that PACs are common in the majority of patients. In more than 50% of 
cases, ERAF episodes were preceded by brady-tachy phenomena, which could be the result of 
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a change in autonomic tone or transient electrical remodelling of the sinus node by AF (122). 
Hoffmann et al. showed that the onset of AF in 97 patients with pacemakers was preceded by 
a heart rate of less than 60 bpm in 33% of 612 episodes of AF (45). These findings highlight 
the importance of other factors than the trigger per se (123). 
 
Role of bradyarrhythmias immediately after successful DC 
The results reported in paper II suggest that sinus bradyarrhythmia in the immediate post-
cardioversion phase was transient and did not predict a recurrence of AF at one week or three 
months.  In two other series of altogether 57 patients, the SN function was studied invasively 
in relation to internal cardioversion (n=37) and AF ablation (n=20), respectively, and 
impaired SN function was found to be reversible and without relevance for AF recurrence 
during short term follow-up (124, 125).   
SN dysfunction might be the result of a remodeling process induced by short periods of atrial 
pacing and longer periods of AF in animals and humans (46, 124-126) . Less is known about 
AF-induced SN remodeling than about AF-induced atrial remodelling (28, 31, 127-129). 
Upon restoration of SR, the reversal of AF-induced atrial electrical remodeling seems to be 
relatively fast (within days) while structural remodeling and its reversal (when possible) is a 
much slower process (over months).  AF is predominantly a condition among elderly people, 
and the same is true for SN dysfunction. While AF is most often symptomatic, signs of slight 
or moderate SN dysfunction may be found in completely asymptomatic persons. In an elderly 
clinical patient population, there is an increased probability of age-related SN impairment, 
myopathic SN dysfunction and drug-induced impairment of SN function, alone or in 
combination (46, 50, 126, 130, 131). The prevalence of AF in patients with SSS might be as 
high as 50% (132, 133), but less is known about the prevalence of significant SN dysfunction 
among patients with persistent AF, and this was much less in our study population. The 
results did not support our original hypothesis that post-cardioversion sinus bradycardia might 
be part of a previously unrecognized SSS. However, there is no single pathognomonic 
criterion for SN dysfunction. Since maintaining automaticity at a functional rate is the main 
task of the SN, indicators of disturbed automaticity and/or sino-atrial conduction have been 
regarded as suitable markers of SN dysfunction. We diagnosed sinus bradycardia according to 
criteria proven to be relatively specific for SN dysfunction, in the range of 90-95% (47, 126, 
134). In the present study, the proportion of patients with SB was 22% (95% CI: 15-29%) and 
it seems that SB appearing in close temporal relation to AF in most cases has a much more 
benign course than when it appears without such relation. 
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RV pacing and clinical heart failure after AVJA for drug resistant AF  
Heart failure is one serious late complication of AF and in patients undergoing AVJA, AF is 
not cured but continues in the atria, while the ventricular rate is dependent on the implanted 
permanent pacemaker. At the time of the planning of the study reported in paper III, there was 
also an ongoing discussion about the benefit/risk scenario for candidates for AVJA. 
Specifically, reports on a small number of patients implied that long-term right ventricular 
stimulation would harm the heart by its non-physiological activation sequence to give rise to 
clinical heart failure and deterioration in many patients. In our single-centre experience, age 
and left ventricular dysfunction were independent predictors of new heart failure, while there 
were no predictors of aggravation of heart failure during follow-up in the study period. This 
would fit with what may be expected in this elderly population. In addition, the all-cause 
mortality of 16% during a mean follow-up period of four years corresponds to an annual all-
cause mortality of ~4%, which is consistent with other reports (69). Four patients were 
confirmed to have died of heart failure, and the cause could not be exactly established in the 
other eight patients.  
New heart failure developed in 22 patients (14%) with only one of these patients dying during 
the follow-up period. Consistent with this, Oczan and al. showed that survival among patients 
with lone AF after AVJA was similar to the expected survival in the overall population, and 
long-term survival was similar for patients with AF, regardless of whether they received 
pharmacological or non-pharmacological therapy (135).  Our findings did not shed light on 
the cause of the development of new heart failure. High age and left ventricular dysfunction 
fit well with continuous progress of the AF related to electromechanical remodeling, but this 
does not exclude the influence of other factors, such as continuous right ventricular pacing 
since AVJA. This applied to all patients, even if those in paroxysmal AF at the time of AVJA 
were programmed into DDD mode. During long-term follow-up, 146 patients were in AF 
versus 115 at baseline, while 58 patients were still in SR as compared to 89 at baseline.  
Theoretically, it should be beneficial to stay in sinus rhythm, and there was no development 
of heart failure or aggravated heart failure in this subgroup during follow-up and no patient 
died of heart failure. This sub-group did not differ in their baseline characteristics from the 
whole group of patients with paroxysmal AF and, as they were treated at the beginning of the 
study period, the length of their follow-up was long. 
AVJA has often been associated with a reduction of symptoms and an improvement in 
exercise tolerance and quality of life, while the effects on the EF have been variable. 
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Improvement has often been seen in the cases of primarily lower EF than normal (136-138), 
while a slight decrease has not been uncommon in patients with an almost normal EF (139). 
Patients with echocardiographically demonstrable intra-ventricular dyssychrony may benefit 
from resynchronization during biventricular pacing by a reduction of symptoms with or 
without improvement of the EF, while the proportion of non-responders remains high, around 
30% (140). It is of note that resynchronization was not available during most of the period 
when our patients underwent AVJA, and none of the patients were upgraded to biventricular 
pacing during the follow-up. 
In previous studies, the ventricular function remained stable or improved after AVJA (68, 
141, 142), while other reports have concluded that long-term right ventricular pacing can 
induce ventricular dyssynchrony and/or a deterioration in heart failure symptoms (70, 71, 
143-145).  
The panorama is changing, and it is more than likely that many of our patients, both with 
paroxysmal and some with persistent AF, would have been candidates for elective AF 
ablation if evaluated for treatment today. Others might have received resynchronization 
therapy, thereby requiring ventricular stimulation. Although the relationship between cause 
and effect cannot be conclusively demonstrated in our retrospective study, the course of 
events during the long follow-up period supported our hypothesis that long-term pacing does 
not frequently induce HF in patients after AVJA. 
 
Prognosis of AF in patients with ischemic heart disease 
The study described in paper IV confirmed that AF in patients with ACS is associated with 
increased short-term mortality and long-term morbidity, and showed that the type of AF is 
important. The study demonstrated that patients with persistent/permanent AF had a poorer 
prognosis than patients with other types of AF during the first 30 days after ACS, but this did 
not remain true in the long-term follow-up. More than half of the patients with any type of AF 
died during long-term follow-up. Patients with new AF at admission and those with known 
paroxysmal AF were more likely to have new hospitalizations for AF during the long-term 
follow-up, and the stroke incidence in patients with known paroxysmal AF was the highest 
observed among the sub-groups.  
Patients with previously known paroxysmal AF had a lower mortality rate than patients with 
new AF at admission or during hospitalization and a higher risk profile at admission. They 
also more often had a history of CHF and coronary artery disease that may have led to their 
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ongoing medication, which may have reduced their risk of dying during the first 30 days after 
ACS.  
Lau et al. showed that new-onset AF conferred poorer in-hospital adverse outcomes and that 
previous AF meant higher long-term (one year) mortality (106). In the GRACE study, new-
onset AF was an independent predictor of in-hospital mortality and other adverse events in 
patients with ACS (107). In our study, previously known paroxysmal AF had a lower 
observed, although not statistically significant, early, i.e. <30 days, mortality compared to that 
of patients in persistent/permanent AF and of those with new AF. As mentioned above, this 
finding might be explained by the fact that patients with previously known AF may have had 
a more appropriate therapy than those with new onset AF, which may have resulted in a better 
short-term prognosis. A few baseline clinical variables were identified as predictors of 
mortality, i.e. age, previous HF, any previous any AMI, diabetes and smoking, which are 
consistent with the results of other studies (106, 107, 146, 147). In our study the impact of all 
predictors was similar across the subgroups with the exception of previous AMI, which 
differed significantly between patients with previously known persistent/permanent AF and 
those with new AF at admission and new AF in hospital, and between patients with 
previously known paroxysmal AF and those with new AF at admission. 
AF type and risk of hospitalization for stroke, AMI or recurrence of AF  
Patients with ACS and without AF had a substantial risk of having a stroke during the ten-
year follow-up, and patients in AF were at a still higher risk with a statistically significant 
difference among the sub-groups, where the highest observed ten-year stroke risk was seen in 
patients with known paroxysmal AF. At admission for ACS, a CHADS2 score ≥ 2 was present 
in 68% of patients with permanent AF, 57% in those with known paroxysmal AF, 43% in 
patients with new AF at admission and 37% in those with new AF developed in-hospital. 
warfarin treatment at admission and at discharge was present in less than half of the patients 
with persistent/permanent AF. In other sub-groups, prescription of warfarin was even less 
frequent, although a slightly increased prescription of warfarin was observed at discharge. In-
hospital stroke was more often seen in patients with new AF after admission. Our findings 
with respect to stroke incidence confirm those of previous studies (99, 107, 148), where AF, 
irrespective of its type, carries an increased risk of stroke during short and long-term follow-
up of patients after ACS. They also confirmed that patients who are eligible for warfarin are 
not always prescribed warfarin. This also holds true when the time period during which the 
patients in the present study were enrolled is taken into consideration. 
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The long-term risk of hospitalization for AMI was similar in the subgroups and similar to that 
of patients without AF.  The risk of subsequent hospitalization for AF was different among 
the subgroups and occurred in more than half of the patients with new AF at admission. 
Hospitalization for AF was generally observed to be higher in patients with paroxysmal AF, 
known or new, than in those with permanent AF. We have only been able to obtain 
information about all relapses leading to a hospitalization, while an unknown number of 
patients may have had recurrences that did not lead to a hospital admission.  
 
Role of the CHADS2 score in patients with ACS, with or without AF 
Paper V reported that the CHADS2 score on admission predicted subsequent death and stroke 
in patients with ACS, with or without known AF. In fact, scores >2 were more predictive of 
these outcomes in patients without AF than with. The CHADS2 score, both unadjusted and 
when adjusted for potential confounders, correlated significantly with all-cause mortality. As 
expected the score was also significantly associated with the rate of hospitalization for stroke. 
This association was strong in patients without AF, both unadjusted and after adjustment for 
potential confounders, while the statistical significance was not sustained after adjustment in 
patients with AF.  
The CHADS2 score was designed to be a scoring system for the risk of stroke in patients with 
AF (110) and can thus be used to guide anticoagulation (4). There is currently limited 
knowledge of the value of the CHADS2 score in patients without known AF (114, 149). 
However, in the present study in patients with ACS, the CHADS2 score proved to be 
valuable, which may seem reasonable since ischemic heart disease per se is often present in 
patients with AF, and all components of the CHADS2 score are common known risk factors 
for ischemic heart disease (150). In fact, 27% of our ACS patients without known AF already 
had a CHADS2 score of ≥2 at admission.  While AF is most often associated with symptoms, 
it may also be asymptomatic.  This means that there may be undiagnosed AF in the group of 
patients without known AF that would indeed justify the use of the CHADS2 score. It is 
impossible for us to know whether or how often this was the case in our patient population, 
but it may contribute to the considerable risk of death or stroke that was found in patients 
without known AF.  
The one-year mortality in patients with AF in the GUSTO I trial was higher than in patients 
without AF, which was in contrast to the data related to in-hospital mortality in that study, 
which showed no difference between the groups (147).   This is consistent with the short and 
long term risks in the present study.  An interesting observation in our study was the high 
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mortality rate among AF patients with a score of 0, which might at least partly be explained 
by the higher proportion of STEMI in this subgroup.  
AF in the TRACE study, which included 6676 consecutive patients with AMI, was associated 
with an increased five-year mortality among in-hospital survivors, regardless of left 
ventricular ejection fraction (LVEF) and symptoms of congestive heart failure, except for 
those with an LVEF <0.25, a subgroup with a poorer prognosis because of heart failure (109). 
In the same investigation, when outcomes after AMI were considered in relation to 
hypertension, the multivariate analysis showed that chronic heart failure, hypertension 
history, increasing age and diabetes were independent risk factors for long-term mortality 
(151). This is in line with the findings in the present study, where mortality was higher as the 
CHADS2 score increased. It is not surprising that patients with higher risk scores had 
increased mortality rates after ACS.  The advantage of the CHADS2 score in comparison with 
other risk scores (152, 153) is that it provides an easy mechanism for clinicians in risk 
evaluation since the score is already in use to assess the risk of thromboembolism in patients 
with AF. 
Little data exist about the incidence of stroke after an ACS. The GUSTO I trial observed an 
incidence of in-hospital ischemic stroke of 0.5% during hospitalization for AMI in patients 
with sinus rhythm (147). This study did not provide data on stroke incidence during follow-
up, and no risk evaluation was made for subsequent stroke. Our study shows that 
hospitalization for stroke is significantly more frequent with higher CHADS2 scores. The 
incidence was higher in patients with AF and highest in patients with a CHADS2 score of 2. 
Interestingly, patients with a CHADS2 score of 1 had a higher risk of being hospitalized for 
stroke during the first four years after hospital admission than those with a CHADS2 score of 
>2. One probable explanation is that AF patients with CHADS2 scores of >2 were identified 
as qualifying for anticoagulation and put on warfarin, which may have reduced the incidence 
of stroke. It is more difficult to explain why the incidence rather abruptly increased after four 
years, but one reason could be the cessation of warfarin due to a lower perceived benefit/risk 
ratio. Equally interesting is that the number of hospitalizations with CHADS2 scores 1 and 2 
started to increase early and substantially, which could be interpreted by pointing out that, in 
the presence of ACS in AF patients, CHADS2 scores of 2 and even 1 confer a high enough 
risk to consider anticoagulation. 
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CONCLUSIONS 
• Premature atrial contractions were common immediately after DC cardioversion in 
patients with persistent AF, in contrast to IRAFs and ERAFs, which were not.  
• The number and characteristics of PACs during the first five minutes after cardioversion 
did not predict recurrence of AF during the first week after restoration of SR.  
• Sinus bradyarrhythmia was relatively common immediately after successful 
cardioversion. It was transient and without prognostic impact on the short-term AF 
recurrence rate.  
• High age and left ventricular dysfunction were predictive of new heart failure during a 
mean of four years of follow-up after AVJA.  
• The majority of patients who underwent AVJA continued to do well during long-term 
follow-up: the development of new symptoms of HF occurred in one eighth of patients 
and HF was aggravated in one fourth of patients with known HF.  
• In patients with ACS, the type of AF affected the subsequent risk of early death and 
hospitalization for stroke and recurrence of AF during long-term follow-up.  
• Long-term mortality was not influenced by the type of AF. 
• The CHADS2 score provided important information about risk and prognosis in patients 
with ACS, both with and without AF. 
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CLINICAL IMPLICATIONS  
 
• The AF episode duration before DC and analysis of triggers of AF onset, including 
underlying rhythm after DC cardioversion, are helpful in selecting individualized therapy. 
• IRAF and ERAF were less common after successful external electrical cardioversion in 
patients with persistent AF than reported after short AF episodes in device studies. 
Although six of eight patients relapsed into AF within a week, the numbers are too small 
to allow the predictive role of IRAF/ERAF in AF recurrence to be conclusively 
determined. 
• Sinus bradycardia or pauses as common transient phenomena in the post-cardioversion 
period were not helpful in predicting AF recurrence. 
• It is reasonable to believe that other factors, such as structure remodelling, in addition to 
or in combination with PACs, contribute to the AF recurrence rate after DC cardioversion 
of patients with persistent AF. 
• Patients with permanent right ventricular pacing did not frequently develop new HF after 
AVJA, while it occurred more often in patients with already known HF. The optimization 
of HF therapy could be considered in those selected patients with drug-resistant persistent 
AF, who are candidates for AVJA. 
• Identification of any type of AF should prompt the evaluation of underlying risk factors. 
• The CHADS2 score was useful in assessing the risk of subsequent events, including stroke 
and mortality, in patients both with ACS with and without AF, and routine use of the 
score will help in optimizing the treatment of important risk factors. 
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